Results 31 to 40 of about 797,089 (324)

Developing mRNA for Therapy

The Keio Journal of Medicine, 2022
Messenger RNA was discovered in 1961 and it took 60 years until the first mRNA became FDA-approved product in the form of COVID-19 mRNA vaccine. During those years a lot of progress has been made by hundreds of scientists. It was 1978 when the first-time isolated mRNA delivered into mammalian cells produced the encoded protein.
openaire   +2 more sources

Siah2 control of T-regulatory cells limits anti-tumor immunity. [PDF]

, 2020
Understanding the mechanisms underlying anti-tumor immunity is pivotal for improving immune-based cancer therapies. Here, we report that growth of BRAF-mutant melanoma cells is inhibited, up to complete rejection, in Siah2-/- mice.
Aifantis, Ioannis, Bosenberg, Marcus, Bradley, Linda M, Brown, Kevin, Dolgalev, Igor, Feng, Yongmei, Hockemeyer, Kathryn, Li, Yan, Marine, Jean-Christophe, Otero, Dennis C, Poźniak, Joanna, Rambow, Florian, Ronai, Ze'ev A, Scortegagna, Marzia, Tinoco, Roberto, Zhang, Tongwu   +15 more
core   +2 more sources

SDF-1α mRNA therapy in peripheral artery disease. [PDF]

Angiogenesis
Abstract Stromal cell-derived factor-1 alpha (SDF-1α) is a promising target for therapeutic angiogenesis in ischemic diseases such as peripheral artery disease (PAD). However, the clinical application of SDF-1α protein or plasmid-based gene therapy is unsuccessful. mRNA therapy has shown great promise in protein replacement.
Zhang T, Zhu B, Deng S, Qin J, Zhang J, Meng S.   +5 more
europepmc   +3 more sources

Epstein-Barr virus lytic infection promotes activation of Toll-like receptor 8 innate immune response in systemic sclerosis monocytes [PDF]

, 2017
BACKGROUND: Monocytes/macrophages are activated in several autoimmune diseases, including systemic sclerosis (scleroderma; SSc), with increased expression of interferon (IFN)-regulatory genes and inflammatory cytokines, suggesting dysregulation of the ...
Dreyfus, David H., FAGGIONI, Alberto, FARINA, Antonella, Farina, G. Alessandra, Lacconi, Valentina, Lenna, Stefania, MORRONE, Stefania, PERUZZI, Giovanna, QUARTA, SILVIA, ROSATO, Edoardo, Trojanowska, Maria, VESTRI, Anna Rita, York, Michael   +12 more
core   +1 more source

Intracranial delivery of synthetic mRNA to suppress glioblastoma

Molecular Therapy: Oncolytics, 2022
Owing to messenger RNA's unique biological advantages, it has received increasing attention to be used as a therapeutic, known as mRNA-based gene therapy.
Hao Peng, Xingrong Guo, Jinjuan He, Chao Duan, Minghuan Yang, Xianghua Zhang, Li Zhang, Rui Fu, Bin Wang, Dekang Wang, Hu Chen, Mengying Xie, Ping Feng, Longjun Dai, Xiangjun Tang, Jie Luo   +15 more
doaj   +1 more source

In Cellulo and In Vivo Comparison of Cholesterol, Beta-Sitosterol and Dioleylphosphatidylethanolamine for Lipid Nanoparticle Formulation of mRNA

Nanomaterials, 2022
Lipid Nanoparticles (LNPs) are a leading class of mRNA delivery systems. LNPs are made of an ionizable lipid, a polyethyleneglycol (PEG)-lipid conjugate and helper lipids.
Ayoub Medjmedj, Albert Ngalle-Loth, Rudy Clemençon, Josef Hamacek, Chantal Pichon, Federico Perche   +5 more
doaj   +1 more source

HER2 and ESR1 mRNA expression levels and response to neoadjuvant trastuzumab plus chemotherapy in patients with primary breast cancer [PDF]

, 2013
Introduction: Recent data suggest that benefit from trastuzumab and chemotherapy might be related to expression of HER2 and estrogen receptor (ESR1). Therefore, we investigated HER2 and ESR1 mRNA levels in core biopsies of HER2-positive breast carcinomas
A Goldhirsch, A Hurtado, A Noske, AA Lazar, AC Wolff, Andre Robidoux, BM Müller, Bruno V Sinn, C Denkert, Carsten Denkert, Christine Solbach, CK Osborne, D Slamon, DG Altman, DJ Dabbs, EA Perez, EH Romond, FL Baehner, G Hennig, G Konecny, G Pentheroudakis, G von Minckwitz, G von Minckwitz, G von Minckwitz, Gunter von Minckwitz, H Joensuu, Hans Tesch, I Pinhel, J Baselga, J Baselga, Jan C Brase, Jens Huober, Judith Prinzler, K Bohmann, Keyur Mehta, Knut Engels, L Gianni, L Gianni, LM McShane, M Bonetti, M Dowsett, M Dowsett, M Filipits, M Untch, M Untch, M Untch, M Untch, Martin-Leo Hansmann, Mattea Reinisch, ME Hammond, Michael Untch, MJ Piccart-Gebhart, MP Fereshteh, PC Roche, Peter A Fasching, Ralf Kronenwett, S Johnston, S Paik, S Paik, Sibylle Loibl, Silvia Darb-Esfahani, T Lahusen, W Zhao   +62 more
core   +1 more source

Viral delivery of antioxidant genes as a therapeutic strategy in experimental models of amyotrophic lateral sclerosis. [PDF]

, 2013
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder with no effective treatment to date. Despite its multi-factorial aetiology, oxidative stress is hypothesized to be one of the key pathogenic mechanisms.
Azzouz, M, Higginbottom, A, Nanou, A, Ning, K, Shaw, P, Valori, CF, Wyles, M   +6 more
core   +1 more source

How mRNA therapeutics are entering the monoclonal antibody field

Journal of Translational Medicine, 2019
In 1975, Milstein and Köhler revolutionized the medical world with the development of the hybridoma technique to produce monoclonal antibodies. Since then, monoclonal antibodies have entered almost every branch of biomedical research.
Lien Van Hoecke, Kenny Roose
doaj   +1 more source

mRNA therapeutics: New vaccination and beyond

Fundamental Research, 2023
The idea of mRNA therapy had been conceived for decades before it came into reality during the Covid-19 pandemic. The mRNA vaccine emerges as a powerful and general tool against new viral infections, largely due to its versatility and rapid development ...
Huan-Huan Wei, Liangliang Zheng, Zefeng Wang   +2 more
doaj   +1 more source